A preclinical study shows that lapatinib inhibits the growth of trastuzumab-resistant ERBB2-positive breast cancer cells and increases apoptosis of anti-ERBB2 antibodies (O'Donovan et al., 2011). This evidence concerns the gene ERBB2 and breast carcinoma.